Gadobutrol/Gadavist-enhanced Cardiac Magnetic Resonance Imaging (CMRI) to Detect Coronary Artery Disease (CAD)
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 426 participants.
Also called NCT01890421
- Study
- In this atlas
Overview
- Design
- Interventional study; allocation not applicable; no masking; primary purpose diagnostic
- Phase
- Phase 3
- Enrolled
- 426 participants
- Sponsor
- Registry
-
NCT01890421 -
2012-002563-10
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States, France, Germany, New Zealand, South Korea, Switzerland, United Kingdom
- Registry status
- Completed
Technical summary
Registry record NCT01890421. Allocation not applicable; no masking; primary purpose diagnostic. Start 2013-07-19 (actual); primary completion 2015-04-10 (actual). Results posted on 2018-05-16.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Gadobutrol/Gadavist-enhanced Cardiac Magnetic Resonance Imaging (CMRI) to Detect Coronary Artery Disease (CAD)
- Acronym
- GadaCAD 1
- Condition
- Coronary Artery Disease
- Intervention (Drug)
- Gadobutrol (Gadovist, Gadavist, BAY86-4875)
- Lead sponsor
- Bayer
Record details
- Record id
cardio:ct-nct01890421- Content hash
dc23e51b289123c6dd2387ee614f77497a161691a905f55ec2b7a6efe09909db